Decitabine plus targeted drugs for advanced blood cancer blast phase
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have a confirmed myeloproliferative neoplasm that has progressed, with at least 5% blasts in blood or bone marrow
- Your kidney and liver tests are within study limits (or the lab results are explained by Gilbert’s disease, blood breakdown, or the MPN itself)
- Your strength is good enough for treatment (ECOG 0–2 or able to do most daily activities; Karnofsky 60% or more)
- You can give informed consent and be willing to get repeat blood/urine and other testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This Phase 2 study tests a gentler weekly combination of two medicines—decitabine and venetoclax—for people with MDS, AML, or MDS/MPN. The goal is to improve blood counts and disease control while reducing side effects compared with more harsh treatments.
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
This trial tests a combination of three drugs (pacritinib, venetoclax, and azacitidine) in people whose myeloproliferative neoplasm (MPN) has progressed to a faster-growing, more aggressive phase (accelerated or blast phase). The goal is to see if this combination is safe and effective.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.